In the subset of people with a history of cardiovascular disease, pregabalin was again associated with an elevated heart ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In t ...

Investing.com -- 4D Molecular Therapeutics (NASDAQ: FDMT) stock rose 36% after the company announced positive 60-week results from its 4D-150 SPECTRA clinical trial in diabetic macular edema (DME) and ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s executive leadership team will host the call, which ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...

Swadeshi Jagran Manch advocates for waiving animal trials in biosimilar approval process to make drugs more affordable and ...

SINGAPORE (Reuters) -Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major ...

KBC notes the announcements made today by the European Banking Authority (EBA) regarding the results of the 2025 EU-wide stress test. A brief set of slides on the KBC data is available at Under the ...

This past year has seen various developments in the field of oncolytic virus therapies - in fundraising and in the clinic.